LENZ Therapeutic announced that the Company has submitted a New Drug Application, NDA, to U.S. Food and Drug Administration, DNA, for LNZ100 (an aceclidine-based ophthalmic solution) for the treatment of presbyopia, a condition impacting an estimated 1.8 billion people globally and 128 million people in the United States.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LENZ:
- LENZ Therapeutics Announces Submission of New Drug Application to U.S. Food and Drug Administration for LNZ100 for the Treatment of Presbyopia
- LENZ Upcoming Earnings Report: What to Expect?
- LENZ Therapeutics to Report Second Quarter 2024 Financial Results on August 14, 2024
- LENZ Therapeutics Secures $30 Million Through Private Share Sale
- Lenz Therapeutics announces $30M investment from Ridgeback Capital